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MaBACKGROUND The RITA-3 (Third Randomised Intervention Treatment of Angina) trial compared outcomes of a routine
early invasive strategy (coronary arteriography and myocardial revascularization, as clinically indicated) to those of a
selective invasive strategy (coronary arteriography for recurrent ischemia only) in patients with non–ST-segment
elevation acute coronary syndrome (NSTEACS). At a median of 5 years’ follow-up, the routine invasive strategy was
associated with a 24% reduction in the odds of all-cause mortality.
OBJECTIVES This study reports 10-year follow-up outcomes of the randomized cohort to determine the impact of a
routine invasive strategy on longer-term mortality.
METHODS We randomized 1,810 patients with NSTEACS to receive routine invasive or selective invasive strategies. All
randomized patients had annual follow-up visits up to 5 years, and mortality was documented thereafter using data from
the Ofﬁce of National Statistics.
RESULTS Over 10 years, there were no differences in mortality between the 2 groups (all-cause deaths in 225 [25.1%]
vs. 232 patients [25.4%]: p ¼ 0.94; and cardiovascular deaths in 135 [15.1%] vs. 147 patients [16.1%]: p ¼ 0.65 in the
routine invasive and selective invasive groups, respectively). Multivariate analysis identiﬁed several independent pre-
dictors of 10-year mortality: age, previous myocardial infarction, heart failure, smoking status, diabetes, heart rate, and
ST-segment depression. A modiﬁed post-discharge Global Registry of Acute Coronary Events (GRACE) score was used to
calculate an individual risk score for each patient and to form low-risk, medium-risk, and high-risk groups. Risk of death
within 10 years varied markedly from 14.4 % in the low-risk group to 56.2% in the high-risk group. This mortality trend
did not depend on the assigned treatment strategy.
CONCLUSIONS The advantage of reduced mortality of routine early invasive strategy seen at 5 years was attenuated
during later follow-up, with no evidence of a difference in outcome at 10 years. Further trials of contemporary intervention
strategies in patients with NSTEACS are warranted. (Third Randomised Intervention Treatment of Angina trial [RITA-3];
ISRCTN07752711) (J Am Coll Cardiol 2015;66:511–20) © 2015 by the American College of Cardiology Foundation.m the *Trent Cardiac Centre, Nottingham University Hospitals, Nottingham, United Kingdom; yLondon School of Hygiene and
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ABBR EV I A T I ON S
AND ACRONYMS
CABG = coronary artery
bypass graft
CI = conﬁdence interval
GRACE = Global Registry of
Acute Coronary Events
GRO = General Register Ofﬁce
HR = hazard ratio
NSTEACS = non–ST-segment
elevation acute coronary
syndrome
ONS = Ofﬁce of National
Statistics
PCI = percutaneous coronary
intervention
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512O ver recent years, 2 alternative man-agement strategies have evolvedfor the management of patients
with non–ST-segment elevation acute coro-
nary syndrome (NSTEACS). The routine
invasive strategy involves early coronary
arteriography within 72 h of an index episode
of myocardial ischemia, and myocardial re-
vascularization as clinically indicated. The
routine invasive strategy deﬁnes the coro-
nary anatomy in all patients and facilitates
selection of the most appropriate treatment
strategy. In contrast, the selective invasive
strategy involves continuation of medical
therapy, with coronary arteriography and
myocardial revascularization reserved forpatients with persistent or recurrent myocardial
ischemia. The selective invasive strategy aims at
identifying patients most likely to beneﬁt from an
invasive procedure, thereby potentially minimizing
the risks and costs of routine invasive management.SEE PAGE 521Several randomized trials have compared routine
invasive and selective invasive strategies in patients
with NSTEACS (1–9). Pooled data from these trials sug-
gest that a routine early invasive strategy reduces the
risk of myocardial infarction, severe angina, and reho-
spitalization (10–12). Moreover, in an individual patient
data meta-analysis of 3 trials reporting long-term
follow-up (FRISC-II [FRagmin and Fast Revascularisa-
tion during InStability in Coronary artery disease];
ICTUS [Invasive versus Conservative Treatment in
Unstable coronary Syndromes], and RITA-3 [Third
Randomised Intervention Treatment of Angina]), a
routine invasive strategy was associated with a lower
risk of death or myocardial infarction over 5 years,
particularly in patients at increased baseline ischemic
risk (13). These results have been incorporated into
national and international clinical guidelines (14–16).
The RITA-3 trial assigned 1,810 patients with
NSTEACS to receive either routine invasive treatment
or selective invasive treatment strategies, and the
short- and medium-term results of the trial have been
reported previously (1,17,18). During the ﬁrst year of
follow-up, the routine invasive strategy approxi-
mately halved the risk of refractory angina, relative to
that of the selective invasive strategy (1). At 5 years,
the routine invasive strategy was associated with an
estimated 26% reduction in the odds of cardiovascu-
lar death and myocardial infarction and a 24%
reduction in the odds of all-cause death (17). Health
economic analysis suggested that a routine invasive
strategy might be cost effective, particularly inpatients at intermediate or high baseline risk (19). In
this report we extended follow-up of RITA-3 patients
to 10 years and assessed the impact of baseline risk on
long-term mortality.
METHODS
The methods of the RITA-3 trial have been reported
previously (1). Brieﬂy, from November 1997 to
October 2001, we enrolled 1,810 patients with
NSTEACS in an open randomized trial of routine
invasive versus selective invasive treatment strate-
gies. Patients were randomized within 48 h of an in-
dex episode of myocardial ischemia if they had
suspected cardiac chest pain at rest and documented
evidence of coronary artery disease with at least 1 of
the following: evidence of ischemia on an electro-
cardiogram; pathological Q waves, suggesting previ-
ous myocardial infarction; or coronary artery disease
on a previous arteriogram. In all cases, the partici-
pating cardiologist had to be uncertain about the
optimal management strategy, and continued medi-
cal therapy had to be an acceptable treatment option.
Patients were excluded if coronary arteriography
was planned within 72 h of the index episode of
myocardial ischemia or if the ischemia was thought to
be due to an arrhythmia, anemia, or noncoronary
disease. RITA-3 recruited patients before the intro-
duction of serum troponin as a routine biomarker of
myocardial necrosis, and patients were excluded if
serum creatine kinase concentration was elevated to
twice the upper limit of normal before randomization.
The trial protocol recommended that all patients
be treated during the index hospital admission with
aspirin and enoxaparin, 1 mg/kg subcutaneously twice
daily for 2 to 8 days. Adenosine diphosphate (ADP)
receptor antagonists and glycoprotein IIb/IIIa re-
ceptor inhibitors were prescribed as clinically appro-
priate. Secondary prevention treatment with aspirin,
beta-blockers, angiotensin-converting enzyme in-
hibitors, and statinswas encouraged in all patients and
was monitored during the ﬁrst 5 years of the trial by a
member of the RITA-3 Executive Committee.
Patients assigned to receive routine invasive
strategy underwent coronary arteriography as soon as
possible and ideally within 72 h of randomization.
The requirement for percutaneous coronary inter-
vention (PCI) or coronary artery bypass graft (CABG)
surgery was guided by the arteriographic ﬁndings,
with no protocol restriction on the use of intra-
coronary stents, other interventional devices, or
pharmacological treatments. All other aspects of pa-
tient management were initiated at the discretion of
the supervising clinician.
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513Patients assigned to receive selective invasive
strategy were managed with antianginal medication,
with the objective of controlling angina symptoms.
Coronary arteriography was indicated only for fail-
ure of the selective invasive strategy, deﬁned by
recurrence of ischemic pain at rest or on minimum
exertion, with transient or persistent electrocardio-
graphic evidence of ischemia despite full antianginal
medication (usually including beta-blockers, ni-
trates, and antithrombotic treatment in clinically
appropriate doses). After discharge from hospital,
coronary arteriography could be performed for ex-
ertional angina despite appropriate antianginal
medication or for evidence of ischemia on functional
testing.
Patients had yearly follow-up examinations at the
hospital to 5 years, to document symptoms, cardiac
events, and vital status. Vital status at 5 years was
known for 1,802 of 1,810 patients (99.6%), and we
have previously reported mortality and rates of
myocardial infarction and revascularization pro-
cedures at that time point (17). The trial was not
designed or funded to collect information on
nonfatal outcomes beyond 5 years, but all surviving
patients were prospectively registered with the Of-
ﬁce of National Statistics (ONS) in England and with
the General Register Ofﬁce (GRO) in Scotland to
ascertain deaths from national mortality data, with
10-year all-cause mortality as the pre-speciﬁed sec-
ondary outcome. A change in ONS policy prevented
collection of mortality information beyond March
2011. Deaths before 5 years were evaluated by an
event validation committee and classiﬁed as car-
diovascular or noncardiovascular. Deaths between
5 and 10 years were classiﬁed as cardiovascular or
noncardiovascular by an investigator blinded to
treatment assignment, on the basis of the cause of
death recorded on the death certiﬁcate.
Multicenter national and local ethics committee
approvals were obtained. All patients provided writ-
ten informed consent to participate in the trial before
randomization.
STATISTICAL ANALYSIS. All analyses were done by
intention to treat. Kaplan-Meier estimates of 10-year
all-cause and cardiovascular mortality were calcu-
lated together with risk differences and conﬁdence
intervals (CIs), and treatment effect was assessed
with a log-rank test. Treatment by time interactions
were used to assess whether any impact of treatment
differed over follow-up time.
To identify baseline characteristics associated
with all-cause mortality, multivariate logistic regres-
sion was used; Cox regression was not appropriatebecause of clear nonproportionality between the
treatment groups. In order to allow for the 220 pa-
tients (12%) with between 9.4 and 10 years’ follow-up
due to the changes in ONS policy, an adjustment was
made by including a covariate of log of total time in
the study for each patient, although this had little
impact on the estimates of effect of the model.
Treatment, age, and sex were included in the model
regardless of their statistical signiﬁcance. Other
candidate baseline variables were added in a stepwise
manner, using a p value of <0.01 as the criterion for
inclusion. A Wald test was used to assess overall
effect for a 3-category variable (e.g., smoking). Time-
updated analyses incorporated myocardial infarction
and revascularization procedures occurring up to
5 years after randomization into the multivariate
model.
In addition, an analysis was undertaken to assess
the impact of the assigned treatment strategy
according to a patient’s underlying risk, using a risk
score developed independently from RITA-3. We
used the post-discharge Global Registry of Acute
Coronary Events (GRACE) model, an external, vali-
dated model that was developed to predict 6-month
mortality in patients with acute coronary syndromes
who survived to hospital discharge (20). This model
was selected because patients enrolled in RITA-3
were randomized in hospital up to 48 h following the
index episode of ischemia and after the very early
high-risk period for further cardiovascular events. A
risk score was calculated for each patient by using a
modiﬁed version of the post-discharge GRACE model
nomogram. RITA-3 was designed before the impact of
renal function on long-term outcome of patients with
acute coronary syndromes was fully recognized, and
baseline renal function was not recorded routinely in
the trial. Renal function, therefore, was excluded
from the risk model, and this approach was validated
previously in a large cohort with acute coronary
syndrome cases in the United Kingdom (21). In
addition, we excluded in-hospital PCI from the risk
model, as the procedures occurred after randomiza-
tion, were strongly inﬂuenced by assigned treatment
strategy, and could potentially confound comparison
of risk scores between treatment strategy groups.
Individual patient risk scores were then used to
stratify patients into low-, medium-, and high-risk
groups such that each group contained approxi-
mately one-third of the deaths. Kaplan-Meier esti-
mates of 10-year all-cause mortality were compared
between the strategies in each risk group. In-
teractions between risk groups and treatment were
used to formally assess whether the impact of treat-
ment differed in the 3 groups on the relative or
TABLE 1 Long-Term Mortality by Treatment Arm
RI (n ¼ 895) SI (n ¼ 915)
Deaths at 10 yrs 225 (25.1) 232 (25.4)
All deaths 249 (27.8) 252 (27.5)
Before 5 yrs 104 138
5–10 yrs 121 94
$10 yrs 24 20
CV deaths at 10 yrs 135 (15.1) 147 (16.1)
CV deaths 148 (16.5) 157 (17.2)
Before 5 yrs 64 92
5–10 yrs 71 55
$10 yrs 13 10
Follow-up, yrs 10.6 10.7
Values are n (%) or n, except Follow-up, which is median.
CV ¼ cardiovascular; RI ¼ routine invasive; SI ¼ selective invasive.
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vidual patient risk scores was used to calculate pre-
dicted 10-year mortality, which was then plotted
against risk score.
RESULTS
Baseline characteristics were well matched between
the randomized groups; the mean age at randomi-
zation was 62 years old, and 38% of patients
were female. Electrocardiographic evidence of myo-
cardial ischemia was present at baseline in 92%,
and 41% had ST-segment deviation of at least
0.1 mV. An elevated level of a serum cardiac
biomarker (creatine kinase or troponin) was detected
in 25%, a history of previous myocardial infarction
was recorded in 28%, and 13% had diabetes at
baseline (1,17).
At 1 year, 86%, 61%, 29%, and 74% (and at 5 years,
80%, 58%, 37%, and 82%) of the patients were taking
aspirin, beta-blocker, angiotensin-converting enzyme
inhibitor, and statin therapy, respectively. There
were no differences between the 2 treatment strategy
groups in the use of any of these medications. Thie-
nopyridines were used routinely in both groups after
implantation of a coronary artery stent.
REVASCULARIZATION PROCEDURES. There was
good separation of treatment strategies between the
randomized groups, and during the index hospital
admission, coronary arteriography was performed
in 857 patients (96%) assigned to routine invasive
strategy and 142 patients (16%) assigned to selective
invasive strategy. In the routine invasive strategy
group, the assigned coronary arteriogram resulted
in revascularization in 397 patients (55%) (consist-
ing of PCI in 35% [stents inserted in 88% of pro-
cedures] and CABG in 21%). In the selective
invasive strategy group, myocardial revasculariza-
tion during the index hospital admission was per-
formed in 94 patients (10%) (consisting of PCI in 7%
and CABG in 4%). During subsequent follow-up, the
rate of revascularization procedures was slightly
lower in the routine invasive group than in the
selective invasive group, and at 5 years, at least
1 revascularization procedure had been carried
out in 546 (61%) and 347 (38%) of the routine
invasive and selective invasive strategy groups,
respectively (17).
ALL-CAUSE AND CARDIOVASCULAR MORTALITY. In
total, 457 deaths (25% of the randomized population)
occurred by 10 years (501 occurred over a median of
10.6 years), including 242 deaths (53%) before 5 years
and 215 deaths (47%) between 5 and 10 years. Deathswere classiﬁed as cardiovascular in 282 cases by 10
years (305 in total), accounting for 62% of all deaths
(Table 1).
Overall, there were no differences in all-cause
mortality between the treatment groups (225
deaths [25.1%] in the routine invasive group vs. 232
deaths [25.4%] in the selective invasive group, for a
risk difference of 0.2%; 95% CI: 4.2% to 3.8%;
p ¼ 0.94). Cardiovascular mortality was also similar
between the 2 groups (135 deaths [15.1%] vs. 147
deaths [16.1%], respectively; p ¼ 0.65). The mortal-
ity curves diverged over the ﬁrst 5 years but then
progressively converged over the following 5 to 10
years (Figures 1 and 2). Rates of all-cause mortality
at 2-year intervals in the routine invasive and
selective invasive arms are shown in Online Table 1.
The hazard ratio (HR) of all-cause mortality in the
routine invasive group versus the selective invasive
group was lower during years 0 to 5 (HR: 0.76; 95%
CI: 0.59 to 0.98) but higher during years 5 to 10 (HR:
1.28; 95% CI: 0.98 to 1.68; p ¼ 0.006 for treatment-
time interaction). Similar results were found for
cardiovascular mortality (HR: 0.70; 95% CI: 0.51 to
0.97; and HR: 1.29; 95% CI: 0.70 to 1.83, for years
0 to 5 and 5 to 10, respectively; treatment-time
interaction p ¼ 0.013).
MULTIVARIATE ANALYSIS. Baseline characteristics
independently associated with all-cause 10-year
mortality are shown in Table 2, and a predictive
model on the basis of these variables showed good
discrimination (c-statistic: 0.809). Variables associ-
ated with all-cause mortality at 10 years were also
associated with all-cause mortality at 5 years
(Online Table 2). Time-updated multivariate anal-
yses suggest that the HR of all-cause mortality
at 10 years was increased by new myocardial
FIGURE 1 All-Cause Mortality by Treatment Group
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FIGURE 2 Cardiovascular Mortality by Treatment Group
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515infarction within 5 years of randomization but was
not associated with revascularization procedures
(Online Tables 3 and 4).
RISK STRATIFICATION. A risk score was calculated
with the modiﬁed post-discharge GRACE score for all
1,810 patients. Patients were stratiﬁed into risk
groups, with approximately equal numbers of deaths
in each group, resulting in low-risk, intermediate-
risk, and high-risk categories that included 63.0%,
22.8%, and 14.2% of the patients, respectively. The
10-year mortality observed across these risk groups
ranged widely from 13.4% in the low-risk group to
58.0% in the high-risk group (Table 3). The median
risk score was 82 (interquartile range [IQR]: 64 to 97),
and the distribution of scores compared with pre-
dicted cumulative 10-year mortality for all patients is
shown in Figure 3. There was close agreement be-
tween predicted and observed 10-year mortality rates
in the 3 risk groups (Figure 3).
Cumulative 10-year mortality by assigned treat-
ment strategy for the 3 risk groups is shown in the
Central Illustration. There were no differences in all-
cause mortality between the routine invasive and
selective invasive strategies in the low-risk and
intermediate-risk categories (Table 3). In the high-
risk subgroup, patients undergoing routine invasive
strategy appeared to be at lower risk of mortality
than patients in the selective invasive group (risk
difference at 5 years was 11.4% [95% CI: 22.8%
to 0.1%]) but this difference was attenuated later
in follow-up because of a low mortality rate in the
selective invasive group. At 10 years, the absolute
risk difference in the high-risk group was 0.3%
(95% CI: 12.4% to 11.7%), and overall, there was
no evidence for an interaction between risk score
and treatment effect on all-cause mortality at 10
years on the relative (p ¼ 0.79) or absolute scale
(p ¼ 0.88).
DISCUSSION
RITA-3 compared outcomes of routine invasive to
those of selective invasive treatment strategies in
patients with NSTEACS, and in a previous report, the
routine invasive strategy was associated with lower
all-cause and cardiovascular mortality at 5 years’
follow-up (17). We extended follow-up of RITA-3 pa-
tients to 10 years and report a progressive diminution
of any mortality differences beyond 5 years, sug-
gesting that the differences in revascularization rates
between the routine invasive and selective invasive
strategies during the index admission (55% versus
10%, respectively) and sustained over 5 years (61% vs.34%, respectively) are not associated with longer-
term survival beneﬁt. It is therefore unclear whether
the mortality difference at 5 years in RITA-3 is due to
a direct treatment effect that attenuates over time,
TABLE 2 Multivariate Analysis of 10-Year Mortality
Risk Factor Deaths
Odds Ratio (95% CI)
(n ¼ 1,808) p Value
Randomized treatment 0.96
SI 232 of 915 (25.4) 1.00
RI 225 of 895 (25.1) 1.00 (0.78 to 1.28)
Age, yrs <0.001
<60 67 of 724 (9.3) 4.43 (3.63 to 5.41) per 10 yrs
61–70 161 of 622 (25.9)
71–80 201 of 422 (47.6)
$80 28 of 42 (66.7)
Heart rate, beats/min <0.001
40–80 316 of 1,398 (22.6) 1.23 (1.12 to 1.34) per 10 beats/min
81–100 122 of 362 (33.7)
$101 19 of 49 (38.8)
Smoking status <0.001
Nonsmoker 78 of 417 (18.7) 1.00
Exsmoker 234 of 806 (29.0) 1.56 (1.11 to 2.18)
Current 144 of 586 (24.6) 2.89 (1.99 to 4.20)
Diabetes <0.001
No 355 of 1,566 (22.7) 1.00
Yes 102 of 244 (41.8) 2.27 (1.64 to 3.14)
Previous MI <0.001
No 280 of 1,309 (21.4) 1.00
Yes 177 of 501 (35.3) 1.75 (1.34 to 2.28)
ST-segment depression <0.001
No 238 of 1,150 (20.7) 1.00
Yes 219 of 660 (33.2) 1.64 (1.28 to 2.10)
Heart failure 0.005
Yes 401 of 1,702 (23.6) 1.00
No 56 of 108 (51.8) 1.93 (1.22 to 3.06)
Sex 0.051
Female 160 of 682 (23.5) 1.00
Male 297/1128 (26.3) 1.30 (1.00 to 1.68)
Values are number of deaths/number of patients (%), unless otherwise noted.
CI ¼ conﬁdence interval; MI ¼ myocardial infarction; other abbreviations as in Table 1.
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516perhaps due to treatment crossovers, or due to the
play of chance.
The relatively low rates of revascularization in the
invasive strategy group in RITA-3 reﬂect practice in
the United Kingdom at the time of enrollment, but
there was clear separation in revascularization rates
between the 2 treatment strategies. Moreover, in otherTABLE 3 All-Cause Mortality by Risk Group
Risk Group Total RI (n ¼ 895)
Low (risk score <90) 153 of 1,140 (13.4) 70 of 554 (12.6)
Medium (risk score 90–107) 155 of 413 (37.5) 81 of 213 (38.0)
High (risk score >107) 149 of 257 (58.0) 74 of 128 (57.8)
Total 457 of 1,810 (25.2) 225 of 895 (25.1)
Values are number of deaths/number of patients (%), unless otherwise noted. Risk group
Coronary Events (GRACE) score (20), which included age, history of congestive heart
(at randomization), ST-segment depression, and elevated cardiac enzymes.
Abbreviations as in Tables 1 and 2.large trials reporting higher revascularization rates, a
routine invasive strategy did not reduce all-cause or
cardiovascular mortality at 5 years (13,22,23). In indi-
vidual patient data meta-analyses of FRISC-II, ICTUS,
and RITA-3, there were no differences in 5-year all-
cause mortality, and a difference in cardiovascular
mortality of borderline statistical signiﬁcance was
driven largely by RITA-3 (13). Hence, deﬁnitive evi-
dence for the impact of a routine invasive strategy on
longer-term mortality is lacking, but our report sug-
gests that, for most patients with NSTEACS, a major
survival beneﬁt over 10 years is unlikely.
The multivariate analysis of RITA-3 patients
reported in this paper identiﬁed several factors that
were independently associated with 10-year mortal-
ity. For example, a 10-year increment in age was
associated with a 4.4-fold increase in the odds of
death, whereas markers of impaired cardiac function
(e.g., history of previous myocardial infarction or
heart failure), and the severity of underlying coronary
artery disease (e.g., ST-segment depression) also had
substantial effects on all-cause mortality.
The multivariate model developed from RITA-3
data showed good discrimination, but we preferred
a modiﬁed post-discharge GRACE score to stratify
individual patients by baseline risk because it was
developed independently of RITA-3 to predict
6-month mortality in patients with acute coronary
syndrome who survived to hospital discharge and
was validated in an unselected cohort of patients
from the large international GRACE registry (20). The
post-discharge GRACE score has not been validated
in external datasets with longer-term follow-up,
but several of the variables included in the score
were also independently associated with 10-year
mortality in RITA-3 (e.g., age, history of heart fail-
ure, ST-segment depression). Moreover the modiﬁed
post-discharge GRACE score was shown to reliably
discriminate between those at higher or lower risk
of 10-year mortality, suggesting that the GRACE
score could be used to predict mortality in the longer
term.SI (n ¼ 915) Odds Ratio (95%) Risk Difference (95% CI)
83 of 586 (14.2) 0.88 (0.62 to 1.23) 1.5% (5.5% to 2.4%)
74 of 200 (37.0) 1.04 (0.70 to 1.55) 1.0% (8.3% to 10.4%)
75 of 129 (58.1) 0.98 (0.60 to 1.62) 0.3% (12.4% to 11.7%)
232 of 915 (25.4) 0.95 (0.76 to 1.20) 0.2% (4.2% to 3.8%)
s were stratiﬁed on the basis of the modiﬁed post-discharge Global Registry of Acute
failure, history of MI, resting heart rate (at randomization), systolic blood pressure
FIGURE 3 Distribution of Modiﬁed Post-Discharge GRACE Score and 10-Year Mortality
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517We used the modiﬁed post-discharge GRACE score
to stratify patients into low-risk, medium-risk, and
high-risk subgroups (Central Illustration). There was
no evidence of beneﬁt from routine invasive man-
agement in the low- and medium-risk groups, which
comprised more than 80% of all patients. We
observed a trend toward beneﬁt in the high-risk
group, with a median difference in survival between
the routine invasive and selective invasive strategies
over 10 years of 1.09 years. If real, the magnitude of
this difference in survival is potentially clinically
important, but these data should be interpreted
cautiously as this post-hoc subgroup analysis is based
on relatively small numbers of deaths and lacks sta-
tistical power, and there was no evidence at 10 years
for an interaction between risk score and treatment.
Further investigation of the effect of underlying risk
on the impact of a routine invasive strategy on
outcome is warranted, and an updated individual
patient data meta-analysis of the FRISC-II, ICTUS,
and RITA-3 trials is planned.
RITA-3 recruited patients considered suitable for
either routine invasive or selective invasive strate-
gies, and patients in whom early coronary arteriog-
raphy was considered inappropriate (or mandatory)
were excluded. The results of RITA-3 therefore
cannot be generalized to the wider unselected popu-
lation of patients with NSTEACS. In RITA-3, the
observed 6-month mortality in the low-, intermedi-
ate-, and high-risk subgroups (deﬁned by the modi-
ﬁed version of the post-discharge GRACE score) was
1.8%, 5.6%, and 8.0%, respectively. These mortality
rates suggest that RITA-3 patients were at low to in-
termediate levels of risk compared with the spectrum
of risk seen in unselected patients with NSTEACS in
the U.K. Myocardial Ischaemia National Audit Project
registry, more than one-half of whom had a 6-month
mortality risk exceeding 9% (24). In both the FRISC-II
and ICTUS trials, mortality rates in the routine and
selective invasive strategy groups at 6 months
were <3% (4,25), and the results of these trials are
therefore also not directly relevant to those patients
with NSTEACS at highest risk. These data suggest that
the randomized trials of routine invasive versus se-
lective invasive strategies in patients with NSTEACS
have consistently excluded patients at highest risk
and that the optimal treatment strategy for these
patients has not been deﬁned.
The long-term results of RITA-3 have important
implications for clinical practice. For most patients
with NSTEACS who are eligible for routine invasive
or selective invasive treatment strategies, neither
strategy confers a prognostic advantage over 10 years.
This lack of prognostic beneﬁt must be balancedagainst the beneﬁcial impact of a routine invasive
strategy on other outcomes, (10–12,17,18,22,23), but,
for many patients at lower levels of baseline risk, a
conservative treatment strategy remains a reasonable
treatment option.
STUDY LIMITATIONS. We relied on national mortality
data to determine vital status during follow-up from
5 to 10 years and classiﬁed deaths after 5 years as
cardiovascular and noncardiovascular on the basis of
the certiﬁed cause of death. In the United Kingdom,
there is a legal requirement that all deaths be regis-
tered with ONS or GRO, but we cannot exclude the
possibility that some deaths were not recorded (for
example, among patients who emigrated) and that
mortality might therefore be underestimated. Never-
theless, Kaplan-Meier plots show relatively constant
mortality over 10 years, suggesting that substantial
underestimation or biased reporting of mortality is
unlikely.
The lack of beneﬁt of reduced mortality from either
treatment strategy at 10 years must be balanced
against earlier reductions in the risk of recurrent
ischemia and myocardial infarction with the routine
invasive strategy (13,17). We did not collect informa-
tion about these endpoints or about revascularization
procedures beyond 5 years, and this limits scope for
exploratory analyses to examine why any mortality
CENTRAL ILLUSTRATION 10-Year Mortality Outcome of a Routine Invasive Strategy Versus a Selective Invasive
Strategy in Non–ST-Segment Elevation Acute Coronary Syndrome
Henderson, R.A. et al. J Am Coll Cardiol. 2015; 66(5):511–20.
Cumulative all-cause mortality by treatment group was stratiﬁed by risk group (low, medium, and high risk, as deﬁned by modiﬁed
pre-discharge Global Registry of Acute Coronary Events [GRACE] score; see Statistical Analysis section for details).
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attenuates during longer-term follow-up. Neverthe-
less, in time-updated multivariate analysis, myocar-
dial infarction during the ﬁrst 5 years of follow-up
was associated with 10-year all-cause mortality,
but revascularization procedures had no substantial
impact on outcome.
RITA-3 recruited patients from 1997 to 2001 and
prior to the availability of drug-eluting stents and
routine use of ADP receptor antagonists in patients
with NSTEACS (15). Evidence from mixed-treatment
comparison meta-analysis suggests that second-
generation everolimus-eluting stents may reduce
mortality relative to that of bare-metal stents (26), but
this beneﬁt has not been demonstrated speciﬁcally in
patients with NSTEACS managed by a routine inva-
sive strategy.
CONCLUSIONS
In the RITA-3 trial of routine invasive versus selective
invasive strategies in patients with NSTEACS, theadvantage of reduced mortality of a routine early
invasive strategy seen at 5 years attenuated during
later follow-up. Risk of death within 10 years was
inﬂuenced by several baseline variables and varied
markedly from 14.4% in the low-risk group to 56.2%
in the high-risk group, but this mortality trend did not
depend on the assigned treatment strategy. Further
trials of contemporary intervention strategies in pa-
tients with NSTEACS are warranted.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Patients
with NSTEACS who are managed with routine invasive
strategies have total and cardiovascular mortality rates
comparable to those of patients managed with selective
invasive strategies over 10 years.
TRANSLATIONAL OUTLOOK: Future trials should
prospectively seek to identify and validate speciﬁc
clinical risk factors that predict beneﬁt from an initially
invasive treatment strategy for patients presenting with
NSTEACS.
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